pharma · NATCOPHARM
Natco Pharma
Natco Pharma: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Price
₹932
Price 2026-07-06
5 day
+0.63%
Short-term move
1 month
+4.32%
Medium-term
Regime
NARROW LEADERSHIP
62% confidence
Market cap
₹17.6k Cr
inflow sector flow
FinGenie AI
Get an intelligence answer grounded in today's published data
“How does today's NARROW LEADERSHIP regime affect Natco Pharma (NATCOPHARM) in the pharma sector?”
Price chart
₹935
+7.04% over period
About Natco Pharma
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
At a Glance
RSI pattern warning
RSI oversold bounces for this stock succeeded only 0% of the time (avg -10.5% over 14 days) — not a reliable pattern.
52-week position
Trading at 76% of 52-week high
Technicals
RSI 14
87.9
Trend
mixed
50 DMA
Below
200 DMA
Above
Key metrics
P/E ratio
12.4
57th pct · 7 quarterly points (limited history)
P/B
1.9
ROE
16.9%
Moderate profitability — 16.9% ROE
Market cap
₹17.6k Cr
Revenue growth
-3960.0% YoY
Promoter
51.0%
52-week range
₹789 – ₹1,226.8
76% of high
RSI (14)
87.9
mixed
vs 50 DMA
Below
DMA ₹1,009.93
Coverage
100/100
HIGH
Quick Take
Natco Pharma: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Peer comparison
| Stock | Price | 5D | P/E | ROE | Rev growth | Mcap |
|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹6,857.5 | +4.6% | 70 | 16.2% | 950% | ₹1.8L Cr |
| CIPLA Cipla | ₹1,472.3 | +1.3% | 30.2 | 11.7% | -210% | ₹1.2L Cr |
| DRREDDY Dr. Reddy's Laboratories | ₹1,367.9 | -0.6% | 26.5 | 11.8% | -1160% | ₹1.1L Cr |
| AUROPHARMA Aurobindo Pharma | ₹1,594.6 | +3.0% | 26.3 | 9.9% | 560% | ₹91.1k Cr |
| ALKEM Alkem Laboratories | ₹5,598.5 | +3.4% | 29.4 | 17.6% | 1460% | ₹67.8k Cr |
| BIOCON Biocon | ₹424.3 | +2.3% | 145.3 | 1.1% | 230% | ₹66.3k Cr |
| GLENMARK Glenmark Pharmaceuticals | ₹2,270.9 | +3.9% | 47 | 14.1% | 1430% | ₹63.9k Cr |
| GLAND Gland Pharma | ₹2,463.2 | +3.8% | 40.9 | 10.5% | 2230% | ₹42.1k Cr |
| NATCOPHARM Natco Pharma | ₹932 | +1.4% | 12.4 | 16.9% | -3960% | ₹17.6k Cr |
Tensions to watch
Promoter holding at 51.0% — neither distress selling nor aggressive buying
No strong insider signal. Watch for changes in promoter stake as a leading indicator.
Key Watchpoints
Breaks above ₹979 (+5%)
Trend reversal confirmation
Breaks below ₹885 (-5%)
Further downside risk
PE reverts to median of 11.6 (7 quarterly points (limited history))
Valuation normalization
Pharma sector holding leadership position
Sector momentum continuing